Nutritional and activity program to support recovery after colon cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Colon cancer patients often lose muscle and nutritional status before and after surgery, which can slow recovery and reduce quality of life. This perioperative study provides routine preoperative nutritional care and then compares postoperative strategies that pair HMB- and vitamin D–enriched hypercaloric/hyperproteic supplementation with a supervised exercise program against standard nutrition and general activity advice. Participants are adults aged 18–75 with stage I–III colon cancer treated at Hospital Universitario Virgen de la Victoria in Málaga, Spain, and are followed through short- and medium-term recovery. Outcomes include muscle strength, physical function, nutritional markers, inflammatory and metabolic biomarkers, and gut microbiota changes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 to 75 years.
* Male and female participants.
* Diagnosis of colon cancer at localized or locally advanced stages (TNM stages I-III).
* Patients scheduled for primary surgical treatment.

Exclusion Criteria:

* Metastatic disease (stage IV)
* Diagnosis of rectal cancer or tumors involving the rectum
* Prior neoadjuvant chemotherapy or radiotherapy before surgery.
* Presence of synchronous malignant tumors.
* Pregnant or breastfeeding women.
* Presence of severe medical conditions, including acute pancreatitis, severe liver or kidney disease, heart failure, severe pulmonary disease, or peripheral arterial disease affecting the lower limbs.
* Diagnosis of anorexia nervosa or other severe eating disorders.
* Known allergy or intolerance to any nutritional supplements used in the study.
* Medical contraindications to moderate-to-vigorous physical activity.
* Regular participation in high-intensity exercise programs.
* High risk of poor adherence to the study procedures, as determined by the study team.

Where it's running

• Hospital Universitario Virgen de la Victoria
  Málaga, Malaga, Spain Recruiting

Study contacts

• Principal investigator: Manuel Macías-Gonzalez, PhD — Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
• Study coordinator: Manuel Macías-González, PhD.
• Email: mmacias.manuel@gmail.com
• Phone: +34 952 36 76 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

• Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer

  This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07840677

• Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer

  This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.

  Recruiting at 3 sites Phase 2 Solstice Oncology, Inc. · Los Angeles, California and 29 other locations · NCT07808151

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.